ECSP024236A - Derivados quimicos y su aplicación como agente antitelomerasa - Google Patents

Derivados quimicos y su aplicación como agente antitelomerasa

Info

Publication number
ECSP024236A
ECSP024236A EC2002004236A ECSP024236A ECSP024236A EC SP024236 A ECSP024236 A EC SP024236A EC 2002004236 A EC2002004236 A EC 2002004236A EC SP024236 A ECSP024236 A EC SP024236A EC SP024236 A ECSP024236 A EC SP024236A
Authority
EC
Ecuador
Prior art keywords
antitelomerasa
application
agent
chemical derivatives
new
Prior art date
Application number
EC2002004236A
Other languages
English (en)
Inventor
Patrick Mailliet
Abdelazize Laoui
Jean Francois Riou
Gilles Doerflinger
Jean Louis Mergny
Francois Hamy
Thomas Caulfield
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ECSP024236A publication Critical patent/ECSP024236A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El presente invento es relativo a la terapia del cáncer y se relaciona con los nuevos agentes anticancerígenos que tienen un mecanismo de acción particular. Implica también los nuevos compuestos químicos así como su aplicación terapéutica en el hombre.
EC2002004236A 2001-03-23 2002-03-22 Derivados quimicos y su aplicación como agente antitelomerasa ECSP024236A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0103916A FR2822468B1 (fr) 2001-03-23 2001-03-23 Derives chimiques et leur application comme agent anti-telomerase

Publications (1)

Publication Number Publication Date
ECSP024236A true ECSP024236A (es) 2003-10-28

Family

ID=8861454

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2002004236A ECSP024236A (es) 2001-03-23 2002-03-22 Derivados quimicos y su aplicación como agente antitelomerasa

Country Status (3)

Country Link
EC (1) ECSP024236A (es)
FR (1) FR2822468B1 (es)
UY (1) UY27211A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2608463C (en) * 2005-05-19 2015-02-03 Prometic Biosciences Inc. Compounds, compositions containing such compounds, and methods of treatment of metastatic melanoma and other cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9206768D0 (en) * 1992-03-27 1992-05-13 Jarman Michael New compounds for use in the treatment of cancer
JPH1160573A (ja) * 1997-08-22 1999-03-02 Nippon Kayaku Co Ltd トリアジン誘導体及びテロメラーゼ阻害剤
US6262053B1 (en) * 1999-06-23 2001-07-17 Parker Hughes Institute Melamine derivatives as potent anti-cancer agents
EE200200263A (et) * 1999-11-29 2003-06-16 Aventis Pharma S.A. Telomeeride G-kvadrupleksstruktuuri fikseerivad ühendid, nende kasutamine ja terapeutilised kombinatsioonid

Also Published As

Publication number Publication date
FR2822468A1 (fr) 2002-09-27
UY27211A1 (es) 2002-08-30
FR2822468B1 (fr) 2008-06-20

Similar Documents

Publication Publication Date Title
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
CY1122417T1 (el) Μεθοδοι και συνθεσεις για παρατεταμενη παροχη φαρμακων
PA8513101A1 (es) Derivados de eteres de pirazol como agentes anti- inflamatorios/analgesicos
CY1112387T1 (el) Θεραπευτικη συνθεση περιεχουσα τουλαχιστον ενα παραγωγο της πυρρολοβενζοδιαζεπινης και φλουδαραβινη
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
UY27890A1 (es) Tratamiento terapeutico
UY28945A1 (es) Derivados de pirrolopiridina
DOP2010000141A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
DOP2010000142A (es) Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales
DOP2005000248A (es) Agentes citotoxicos que comprendentaxanos nuevos.
GT200500026A (es) Derivados de beta-aminoacidos como inhibidores del factor xa.
PA8654601A1 (es) Agentes citotoxicos que comprenden taxanos nuevos
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
BRPI0518448A2 (pt) composiÇÕes farmacÊuticas compreendendo um derivado de camptotecina
UY27812A1 (es) Uso de docetasel-doxorubin-ciclofosfamida como apoyo de terapias
PA8508201A1 (es) Derivados de heterociclo-alquilsulfonil pirazolo como agentes anti-inflamatorios/analgesicos
UY27418A1 (es) Formulaciones en combinación de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilización
CL2007002878A1 (es) Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.
MY130957A (en) Triazine derivatives and their application as antitelomerase agents
BR0302590A (pt) Agente para tratamento de tumores sólidos
ECSP024236A (es) Derivados quimicos y su aplicación como agente antitelomerasa
SV2001000212A (es) Una combinacion de agentes antineoplasticos que comprenden acetildinalina y paclitaxel y/o carboplatina y juego que la comprende